Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug.

Cipla has secured USFDA approval to market a generic version of Abraxane, paclitaxel protein-bound particles for injectable ...

Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Therapies that unleash the immune system to fight tumors have greatly extended the lives of people with many types of cancer.

A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

On March 5, 2025, the FDA cleared an investigational new drug application for CTD402, a CD7-targeted universal CAR T-cell therapy, for the treatment of pediatric and adult patients with ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

Discover why Immutep's Eftilagimod Alpha shows promise in NSCLC and HNSCC trials, but cautious investment is advised. Explore more details here.

Report commissioned by govt analysed cost-effectiveness of 2 medicines, comparing them to to chemo in patients with newly ...

With that said, the extent of metastasis can vary along with the prognosis ... Moreover, the location of the tumor—whether in the airways (as with bronchioloalveolar adenocarcinoma) or in lung tissues ...